Literature DB >> 21565206

Effects of adrenaline in human colon adenocarcinoma HT-29 cells.

Helen P S Wong1, Judy W C Ho, Marcel W L Koo, Le Yu, William K K Wu, Emily K Y Lam, Emily K K Tai, Joshua K S Ko, Vivian Y Shin, Kent Man Chu, Chi Hin Cho.   

Abstract

AIMS: Stress has been implicated in the development of cancers. Adrenaline levels are increased in response to stress. The effects of adrenaline on colon cancer are largely unknown. The aims of the study are to determine the effects of adrenaline in human colon adenocarcinoma HT-29 cells and the possible underlying mechanisms involved. MAIN
METHODS: The effect of adrenaline on HT-29 cell proliferation was determined by [(3)H] thymidine incorporation assay. Expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) were detected by Western blot. Matrix metalloproteinase-9 (MMP-9) activity and prostaglandin E(2) (PGE(2)) release were determined by zymography and enzyme immunoassay, respectively. KEY
FINDINGS: Adrenaline stimulated HT-29 cell proliferation. This was accompanied by the enhanced expression of COX-2 and VEGF in HT-29 cells. Adrenaline also upregulated MMP-9 activity and PGE(2) release. Adrenaline stimulated HT-29 cell proliferation which was reversed by COX-2 inhibitor sc-236. COX-2 inhibitor also reverted the action of adrenaline on VEGF expression and MMP-9 activity. Further study was performed to determine the involvement of β-adrenoceptors. The stimulatory action of adrenaline on colon cancer growth was blocked by atenolol and ICI 118,551, a β(1)- and β(2)-selective antagonist, respectively. This signified the role of β-adrenoceptors in this process. In addition, both antagonists also abrogated the stimulating actions of adrenaline on COX-2, VEGF expression, MMP-9 activity and PGE(2) release in HT-29 cells. SIGNIFICANCE: These results suggest that adrenaline stimulates cell proliferation of HT-29 cells via both β(1)- and β(2)-adrenoceptors by a COX-2 dependent pathway.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565206     DOI: 10.1016/j.lfs.2011.04.007

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  25 in total

1.  Analysis of the correlation among hypertension, the intake of β-blockers, and overall survival outcome in patients undergoing chemoradiotherapy with inoperable stage III non-small cell lung cancer.

Authors:  Pei Yang; Weiye Deng; Yaqian Han; Yingrui Shi; Ting Xu; Juan Shi; Hesham Elhalawani; Yu Zhao; Xiaoxue Xie; Fan Lou; Rong Zhang; Hekun Jin
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

2.  Exploring a structural protein-drug interactome for new therapeutics in lung cancer.

Authors:  Xiaodong Peng; Fang Wang; Liwei Li; Khuchtumur Bum-Erdene; David Xu; Bo Wang; Anthony A Sinn; Karen E Pollok; George E Sandusky; Lang Li; John J Turchi; Shadia I Jalal; Samy O Meroueh
Journal:  Mol Biosyst       Date:  2014-01-09

3.  Optimal Management of a Synchronous Diagnosis of Phaeochromocytoma and Colorectal Neoplasia.

Authors:  Ridwaan Sohawon; Peter Truran; Jonathan Webster; Barney J Harrison; Sabapathy P Balasubramanian
Journal:  Indian J Surg Oncol       Date:  2017-02-22

Review 4.  The role of ADRB2 gene polymorphisms in malignancies.

Authors:  Yaqian Wang; Shujuan Jiang
Journal:  Mol Biol Rep       Date:  2021-03-06       Impact factor: 2.316

Review 5.  β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives.

Authors:  Marisa Coelho; Cátia Soares-Silva; Daniela Brandão; Franca Marino; Marco Cosentino; Laura Ribeiro
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-05       Impact factor: 4.553

Review 6.  Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement.

Authors:  Elad Neeman; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2012-04-04       Impact factor: 7.217

7.  Exposure to ACEI/ARB and β-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer.

Authors:  Diana R Engineer; Basil O Burney; Teresa G Hayes; Jose M Garcia
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243

8.  Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.

Authors:  S Sud; C O'Callaghan; C Jonker; C Karapetis; T Price; N Tebbutt; J Shapiro; G Van Hazel; N Pavlakis; P Gibbs; M Jeffrey; L Siu; S Gill; R Wong; D Jonker; D Tu; R Goodwin
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

9.  Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.

Authors:  Monique B Nilsson; Huiying Sun; Lixia Diao; Pan Tong; Diane Liu; Lerong Li; Youhong Fan; Alissa Poteete; Seung-Oe Lim; Kathryn Howells; Vincent Haddad; Daniel Gomez; Hai Tran; Guillermo Armaiz Pena; Lecia V Sequist; James C Yang; Jing Wang; Edward S Kim; Roy Herbst; J Jack Lee; Waun Ki Hong; Ignacio Wistuba; Mien-Chie Hung; Anil K Sood; John V Heymach
Journal:  Sci Transl Med       Date:  2017-11-08       Impact factor: 17.956

10.  Bedside to bench: role of muscarinic receptor activation in ultrarapid growth of colorectal cancer in a patient with pheochromocytoma.

Authors:  Erik C von Rosenvinge; Kunrong Cheng; Cinthia B Drachenberg; Carol B Fowler; David L Evers; Guofeng Xie; Jean-Pierre Raufman
Journal:  Mayo Clin Proc       Date:  2013-10-04       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.